Immune checkpoint crosstalk: CTLA-4/CD80 engagement as a predictor of anti-PD-1/PD-L1 therapy outcome in NSCLC - Quiz - MDSpire

Immune checkpoint crosstalk: CTLA-4/CD80 engagement as a predictor of anti-PD-1/PD-L1 therapy outcome in NSCLC

  • By

  • Juan Gumuzio

  • James Miles

  • Nicole Quimi

  • Markel Rementeria

  • Cristina Cacho

  • Laura Camacho

  • Erica J. Geraedts

  • Kim van Elst

  • Fernando Aguirre

  • Peter J. Parker

  • Véronique Calleja

  • July 16, 2026

Share

Original Source(s)

Immune checkpoint crosstalk: CTLA-4/CD80 engagement as a predictor of anti-PD-1/PD-L1 therapy outcome in NSCLC

  • by Juan Gumuzio, James Miles, Nicole Quimi, Markel Rementeria, Cristina Cacho, Laura Camacho, Erica J. Geraedts, Kim van Elst, Fernando Aguirre, Peter J. Parker, Véronique Calleja

  • July 16, 2026

Related Content

Functional brain connectivity correlates of pain relief during virtual reality exposure in cancer patients

Proteomics and transcriptomics reveal molecular subtypes and biomarkers of advanced cutaneous T-cell lymphoma

Case Report: Immune checkpoint inhibitor-induced IgG4-related disease mimicking renal metastatic progression: successful steroid-sparing management with rituximab